SonoThera™ to Present Four Abstracts at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
April 30 2024 - 8:30AM
Business Wire
- Abstracts highlight SonoThera’s novel, ultrasound-guided
nonviral gene therapy platform’s ability to non-invasively deliver
nucleic acid payloads of diverse formats and sizes to targeted
organs and tissues.
- ASGCT presentations highlight targeted DNA delivery to the
kidney and liver resulting in durable gene expression, the ability
to re-dose and dose titrate with exemplary safety and
efficacy.
SonoThera™, a biotechnology company dedicated to treating the
root cause of human diseases through genetic therapy, today
announced that it will present four abstracts at the 27th annual
meeting of the American Society of Gene and Cell Therapy (ASGCT)
taking place in Baltimore, Maryland, May 7-11, 2024.
All four presentations feature SonoThera’s ultrasound-guided
nonviral gene therapy platform, which is being developed to
non-invasively deliver nucleic acid payloads of diverse formats and
sizes. While the platform is designed to selectively target a wide
range of organs within the body, research presented at ASCGT
focuses on the targeted delivery of redosable and therapeutically
relevant DNA payloads that result in robust and durable gene
expression in the kidney and liver in murine and NHP models.
“We are pleased to share our recent research further advancing
our technology,” said Kenneth Greenberg, PhD, CEO of SonoThera.
“Our scientific team’s innovation demonstrates our commitment to
realizing the enormous potential of ultrasound as an effective,
nonviral delivery method which may solve some of today’s biggest
challenges in genetic medicine. We look forward to presenting these
results at ASGCT.”
Poster Presentation Details:
Title: Kidney-targeted non-viral gene delivery using a
novel noninvasive transcutaneous ultrasound delivery platform
enables redosable, titratable, and durable gene expression in
healthy mice and NHPs, and polycystic kidneys mouse model.
Presenter: Bert Frederich, PhD Session Date/Time:
Friday, May 10, 12:00pm - 1:30pm, Exhibit Hall Abstract
Number: 1740 Title: Targeted non-viral gene delivery
through transcutaneous ultrasound enables rapid, robust, redosable,
titratable, and durable gene expression in the liver in murine and
NHP models. Presenter: Surabhi Rao, MSc Session
Date/Time: Thursday, May 9, 12:00pm - 1:30pm, Exhibit Hall
Abstract Number: 1228 Title: Cellular phenotyping of
non-human primate and mouse kidney and liver following a novel
targeted transcutaneous ultrasound-mediated gene delivery
demonstrates gene expression in clinically relevant cell types.
Presenter: Katie Benthall, PhD Session Date/Time:
Friday, May 10, 12:00pm - 1:30pm, Exhibit Hall Abstract
Number: 1735 Title: Development of a next-generation
non-viral human FVIII therapeutic administered through targeted
transcutaneous ultrasound enables normal physiological levels of
FVIII transgene expression in a redosable and titratable manner.
Presenter: Margot Krivega, PhD Session Date/Time:
Thursday, May 9, 12:00pm - 1:30pm, Exhibit Hall Abstract
Number: 1229
About SonoThera™
Founded by Drs. Kenneth Greenberg, Michael Davidson, and Steve
Feinstein, SonoThera, Inc. is a biotechnology company dedicated to
treating the root cause of human disease through genetic therapy.
SonoThera is developing an ultrasound-guided, nonviral gene therapy
platform treatments designed to provide patients with the next
generation of safe and effective genetic medicines. The platform
utilizes sonoporation, a microbubble-mediated biophysical process
to non-invasively deliver genetic payloads selectively targeting a
wide range of organs within the body. SonoThera is headquartered in
South San Francisco, California. Visit www.sonothera.com to learn
more.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430291799/en/
Investor Inquiries: investors@sonothera.com Media
Inquiries: Mog & Springer Communications on behalf of
SonoThera, Inc. Elizabeth Harness, Principal, P: +1
585-435-7379, elizabeth.harness@mogandspringer.com